MedTrace Logo

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

NCT01336738 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2013-08-06

Study results available
· View outcomes & findings →

Summary

B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.

Conditions

  • Diabetes, Type 2

Interventions

DRUG

Placebo

Tablets (n=6), 0 mg, once daily for 84 days

DRUG

150 mg PF-04991532

Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days

DRUG

450 mg PF-04991532

Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days

DRUG

750 mg PF-04991532

Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days

DRUG

Sitagliptin 100 mg

Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States
  • Canada
  • Hungary
  • Mexico
  • Slovakia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336738 on ClinicalTrials.gov